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ABSTRACT	
During	tobacco	and	e-cigarette	use,	nicotine	is	mainly	metabolized	in	the	human	liver	by	 CYP2A6.	 Given	 that	 a	 slower	 CYP2A6	 metabolism	 has	 been	 associated	 with	 less	vulnerability	to	develop	nicotine	dependence,	the	current	studies	sought	to	validate	a	novel	CYP2A6	 inhibitor,	 5-(4-ethylpyridin-3-yl)thiophen-2-yl)methanamine	 (DLCI-1),	 for	 its	effects	on	intravenous	nicotine	self-administration.	Male	and	female	mice	were	trained	to	self-administer	nicotine	across	daily	sessions.	Once	stable	responding	was	achieved,	DLCI-1	or	vehicle	control	were	administered	prior	to	nicotine	sessions.	We	found	that	the	lower	25	mg/kg	and	moderate	50	mg/kg	doses	of	DLCI-1	induced	a	significant	decrease	in	nicotine	intake	for	both	males	and	females.	DLCI-1	was	further	shown	to	be	more	effective	than	a	moderate	 1	mg/kg	 dose	 of	 bupropion	 on	 reducing	 nicotine	 intake	 and	 did	 not	 exert	 the	adverse	behavioral	effects	found	with	a	high	75	mg/kg	dose	of	bupropion.	Although	mice	treated	with	DLCI-1	self-administered	significantly	less	nicotine,	similar	nicotine-mediated	behavioral	 effects	 on	 locomotion	 were	 observed.	 Together,	 along	 with	 the	 analysis	 of	nicotine	metabolites	during	self-administration,	these	findings	support	the	contention	that	blocking	 hepatic	 nicotine	 metabolism	 would	 allow	 for	 similar	 activation	 of	 nicotinic	acetylcholine	 receptors	 at	 lower	 nicotine	 doses.	 Moreover,	 these	 effects	 of	 DLCI-1	 were	specific	to	nicotine	self-administration,	as	DLCI-1	did	not	result	in	any	behavioral	changes	during	 food	 self-administration.	Taken	 together,	 these	 studies	 validate	DLCI-1	 as	 a	novel	compound	 to	 decrease	 nicotine	 consumption,	 which	 may	 thereby	 promote	 tobacco	 and	nicotine	product	cessation.	
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Significance	Statement	
Current	pharmacological	 approaches	 for	nicotine	 and	 tobacco	 cessation	have	only	been	able	 to	achieve	 limited	efficaciousness	 in	promoting	 long-term	abstinence.	Here,	we	characterize	the	effects	of	a	novel	compound,	DLCI-1,	which	inhibits	the	main	enzyme	that	metabolizes	 nicotine,	 and	 we	 report	 a	 significant	 decrease	 in	 intravenous	 nicotine	 self-administration	 in	 male	 and	 female	 mice,	 supporting	 the	 potential	 of	 DLCI-1	 as	 a	 novel	tobacco	cessation	pharmacotherapeutic.	 	
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INTRODUCTION	
Tobacco	 addiction	 remains	 a	 leading	 preventable	 cause	 of	 disease	 and	 death	worldwide,	despite	a	high	percentage	of	individuals	expressing	a	desire	to	quit	(CDC,	2015).	Nicotine,	the	main	psychoactive	component	in	tobacco,	exerts	its	reinforcing	effects	by	acting	on	 neuronal	 nicotinic	 acetylcholine	 receptors	 (nAChRs)	 in	 the	 brain	 (Albuquerque	 et	 al.,	1995;	Lena	and	Changeux,	1998;	Tuesta	et	al.,	2011).	Although	 tobacco	cigarette	use	has	declined	recently,	this	has	unfortunately	been	contrasted	with	a	dramatic	increase	in	the	use	of	e-cigarettes,	which	deliver	vaporized	nicotine	(GBD,	2017).	While	e-cigarettes	have	been	promoted	 as	 tobacco	 cessation	 aids,	 product	 consumption	 by	 never-smokers	 has	 raised	significant	concerns	for	addiction	liability,	especially	among	youth	(Etter	and	Bullen,	2014;	Gornall,	2015;	Primack	et	al.,	2015).			 In	humans,	the	majority	of	nicotine	is	metabolized	to	nicotine-∆1’-5’-iminium	ion	by	the	hepatic	enzyme,	cytochrome	P450	2A6	(CYP2A6),	followed	by	the	conversion	to	cotinine	by	 either	 CYP2A6	 itself,	 or	 through	 the	 subsequent	 action	 of	 aldehyde	 oxidase	 or	 other	enzymes	 (Ray	 et	 al.,	 2009;	Raunio	 and	Rahnasto-Rilla,	 2012;	 von	Weymarn	 et	 al.,	 2012).	Allelic	variation	in	the	gene	encoding	for	CYP2A6	in	humans	has	been	associated	with	altered	nicotine	metabolism,	resulting	in	a	differential	vulnerability	to	nicotine	dependence,	related	to	the	rate	of	metabolism	(Ray	et	al.,	2009;	Thorgeirsson	et	al.,	2010).	The	CYP2A6	gene	is	highly	 polymorphic	with	 allelic	 variants	 resulting	 in	 either	 lower	 or	 increased	metabolic	function	(Mwenifumbo	et	al.,	2008;	Thorgeirsson	et	al.,	2010;	Raunio	and	Rahnasto-Rilla,	2012).	 Importantly,	 individuals	 with	 a	 slow	 metabolizer	 CYP2A6	 genotype	 are	 less	vulnerable	to	develop	tobacco	dependence	than	normal	metabolizers	(Audrain-McGovern	et	
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al.,	 2007;	 Thorgeirsson	 et	 al.,	 2010;	 Bloom	 et	 al.,	 2011).	 It	 is	 predicted	 that	 a	 slower	metabolism	would	result	in	more	prolonged	actions	of	nicotine	following	drug	consumption.	Therefore,	with	lower	levels	of	nicotine	intake,	the	amount	of	drug	remaining	in	the	system	would	accumulate	over	 time,	and	 thus,	 less	drug	would	be	 required	 to	achieve	sustained	activation	of	nAChRs	in	mesolimbic	brain	pathways	mediating	reinforcement	(Tuesta	et	al.,	2011;	Fowler	and	Kenny,	2014).	However,	under	conditions	of	 increasing	nicotine	intake,	activation	of	the	pathways	regulating	the	aversive	properties	of	the	drug,	such	as	the	medial	habenulo-interpeduncular	 pathway,	 would	 be	 more	 readily	 engaged,	 resulting	 in	 a	downward	behavioral	titration	of	drug	consumption	(Fowler	et	al.,	2011;	Fowler	and	Kenny,	2014).	 Supporting	 this	 contention,	 slow	 metabolizers	 have	 been	 found	 to	 consume	 less	nicotine	per	day,	experience	less	withdrawal	symptoms,	and	are	more	successful	in	quitting	smoking	(Strasser	et	al.,	2007;	Patterson	et	al.,	2008;	Rodriguez	et	al.,	2011;	Liakoni	et	al.,	2019).	 Conversely,	 individuals	with	 a	 higher	 rate	 of	metabolism	 exhibit	 greater	 levels	 of	nicotine	intake,	withdrawal	symptoms	and	drug	craving	(Strasser	et	al.,	2011;	Chen	et	al.,	2018a;	Liakoni	et	al.,	2019),	which	may	thereby	 increase	 the	 likelihood	of	relapse	during	cessation.	In	a	study	with	the	cessation	therapeutic	bupropion,	it	was	found	that	individuals	with	a	slow	metabolism	are	similarly	successful	 in	achieving	abstinence	under	placebo	or	bupropion	 conditions,	 whereas	 fast	 metabolizers	 show	 greater	 benefit	 from	 bupropion	treatment	(Patterson	et	al.,	2008).	Given	these	findings	in	humans	and	the	consideration	that	individuals	 with	 allelic	 variation	 appear	 to	 function	 normally	 despite	 having	 a	 reduced	CYP2A6	metabolism,	drug	development	efforts	to	limit	nicotine	metabolism	represents	an	exciting	opportunity	for	therapeutic	modulation.	Indeed,	initial	drug	validation	efforts	along	these	 lines	 have	 proven	 to	 be	 effective	 in	 smokers.	 Methoxsalen	 was	 shown	 to	 inhibit	
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CYP2A6,	and	in	smokers,	methoxsalen	decreased	nicotine	metabolism	and	reduced	cigarette	consumption	 (Sellers	et	al.,	2000).	Conceptually,	 this	approach	could	 lead	 to	a	 significant	reduction	 in	 tobacco	 product	 use,	 thereby	 limiting	 exposure	 to	 harmful	 constituents	mitigating	adverse	health	effects,	and/or	provide	the	means	for	an	individual	to	gradually	reduce	 intake	 over	 time	 to	 eventually	 achieve	 full	 smoking	 cessation,	 potentially	 in	combination	with	other	therapeutics.						 Recently,	we	developed	a	potent	and	selective	CYP2A6	inhibitor,	DLCI-1,	which	was	shown	to	exhibit	favorable	metabolic	stability	and	half-life	in	human	liver	microsomes	and	adheres	to	Lipinski’s	rule	of	five	for	drug	likeness	(Denton	et	al.,	2018).	Here,	we	examined	whether	DLCI-1	would	be	effective	 in	mediating	nicotine	consumption	 in	both	males	and	females	in	a	mouse	model.	The	intravenous	nicotine	self-administration	procedure	was	used	as	 it	 allows	 for	 the	 most	 direct	 and	 reliable	 measure	 of	 nicotine	 reinforcement	 in	 mice	(Fowler	and	Kenny,	2011).	We	also	assessed	the	effects	of	the	approved	smoking	cessation	therapeutic,	bupropion,	on	nicotine	self-administration,	as	a	means	of	comparing	DLCI-1’s	relative	effectiveness	in	reducing	nicotine	intake.	As	a	secondary	behavioral	measure,	mice	were	examined	for	nicotine-mediated	changes	in	locomotion.	Finally,	to	ensure	that	DLCI-1	was	selective	 for	decreasing	nicotine	 intake,	as	opposed	 to	a	general	attenuation	of	 lever	pressing	behavior,	the	effect	of	DLCI-1	was	assessed	during	food	self-administration.			
MATERIALS	AND	METHODS	
Animals	
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Male	 and	 female	 wildtype	 C57BL/6J	 mice	 were	 derived	 from	 breeders	 in	 our	laboratory	animal	facilities	or	were	purchased	from	the	Jackson	Laboratory	(Bar	Harbor,	ME,	USA).	Mice	were	maintained	in	an	environmentally	controlled	vivarium	on	a	12	h	reversed	light/dark	 cycle.	 Food	 and	 water	 were	 provided	 ad	 libitum	 until	 behavioral	 training	commenced.	During	food	training,	subjects	were	mildly	food	restricted	to	85–90%	of	their	free-feeding	 bodyweight,	 and	 water	 was	 provided	 ad	 libitum.	 All	 experiments	 were	conducted	 in	 strict	 accordance	 with	 the	 NIH	 Guide	 for	 the	 Care	 and	 Use	 of	 Laboratory	Animals	 and	were	 approved	 by	 the	 Institutional	 Animal	 Care	 and	 Use	 Committee	 at	 the	University	of	California,	Irvine.		
Drugs			 (-)-Nicotine	 hydrogen	 tartrate	 salt	 (MP	 Biomedicals,	 Santa	 Ana,	 CA,	 USA;	0215355491)	 was	 dissolved	 in	 0.9%	 sterile	 saline	 and	 adjusted	 to	 pH	 7.4.	 The	 CYP2A6	inhibitor,	(5-(4-ethylpyridin-3-yl)thiophe-2-yl)methanamine	(DLCI-1),	was	prepared	as	the	hydrochloride	salt,	as	previously	described	(Denton	et	al.,	2018),	and	then	dissolved	in	0.9%	sterile	saline,	adjusted	to	pH	7.4,	and	administered	at	a	dose	of	25	or	50	mg/kg.	Doses	were	derived	 by	 combining	 the	 generally	 accepted	 dose	 of	 5	mL/kg	 and	 the	 IC50	 value	 of	 the	compound	against	CYP2A6	(Denton	et	al.,	2018).	Both	DLCI-1	and	vehicle	were	administered	p.o.	via	oral	gavage	at	a	volume	of	0.1	mL.	Bupropion	(Sigma	Aldrich,	St.	Louis,	MO,	USA;	B102)	was	dissolved	 in	0.9%	sterile	saline	and	administered	at	a	dose	of	1	or	75	mg/kg,	which	was	injected	intraperitoneally	at	a	volume	of	10	ml/kg.	For	liquid	chromatography	-	mass	spectrometry	analysis	of	blood	samples,	nicotine-methyl-D3	and	cotinine-methyl-D3,	
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trans-3′-hydroxycotinine-methyl-D3,	 and	 standards	 (nicotine,	 cotinine	 and	 trans-3′-hydroxycotinine)	were	obtained	from	Toronto	Research	Chemicals	(North	York,	Canada).	
	
Intravenous	nicotine	self-administration	Subjects	were	food	trained	and	then	surgically	catheterized	as	previously	described	(Fowler	et	al.,	2011;	Chen	et	al.,	2018b).	Briefly,	mice	were	anesthetized	with	an	isoflurane	(1-3%)/oxygen	vapor	mixture	and	prepared	with	intravenous	catheters.	Catheters	consisted	of	a	6	cm	length	of	silastic	tubing	fitted	to	a	guide	cannula	(Plastics	One,	Roanoke,	VA)	bent	at	 a	 curved	 right	 angle	 and	 encased	 in	 dental	 acrylic.	 The	 catheter	 tubing	 was	 passed	subcutaneously	 from	the	animal’s	back	to	the	right	 jugular	vein,	and	a	1	cm	length	of	 the	catheter	 tip	 was	 inserted	 into	 the	 vein	 and	 tied	 with	 surgical	 silk	 suture.	 Following	 the	surgical	 procedure,	 animals	were	 allowed	 ≥48	 h	 to	 recover	 from	 surgery,	 then	 provided	access	to	respond	for	food	reward	until	criteria	were	achieved.	Mice	were	then	permitted	to	acquire	 intravenous	 nicotine	 self-administration	 during	 1	 h	 daily	 sessions,	 6-7	 days	 per	week,	at	 the	standard	 training	dose	of	nicotine	 (0.03	mg/kg/infusion)	 for	eight	days	and	were	then	transitioned	onto	the	moderate	0.1	mg/kg/infusion	dose	of	nicotine.	This	dose	was	chosen	since	mice	exhibit	the	highest	level	of	responding	for	this	dose	across	the	dose	response-curve,	and	it	also	results	in	a	similar	level	of	intake	as	that	found	at	higher	doses	with	behavioral	 titration	via	 self-administration	 (Fowler	 and	Kenny,	2011).	Nicotine	was	delivered	 through	 tubing	 into	 the	 intravenous	 catheter	 by	 a	 Razel	 syringe	 pump	 (Med	Associates).	Each	 session	was	performed	using	2	 retractable	 levers	 (1	active,	1	 inactive).	Completion	 of	 the	 response	 criteria	 on	 the	 active	 lever	 resulted	 in	 the	 delivery	 of	 an	
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intravenous	nicotine	infusion	(0.03	mL	infusion	volume;	FR5TO20	sec	schedule).	Responses	on	the	inactive	lever	were	recorded	but	had	no	scheduled	consequences.		After	acquisition	and	achieving	stable	responding	on	the	0.1	mg/kg/infusion	dose,	subjects	were	examined	for	the	effects	of	DLCI-1	or	bupropion	on	nicotine	intake.	For	Cohort	1	(n=5	males),	mice	were	orally	administered	DLCI-1,	or	vehicle	control,	30	minutes	prior	to	each	session	utilizing	a	within	subject	Latin-square	design.	Following	these	sessions,	mice	were	placed	 into	 the	open	 field	 for	 locomotor	assessments	 (see	below).	 In	between	each	DLCI-1	or	vehicle	administration	session,	subjects	were	provided	baseline	days	to	ensure	stable,	reinstated	responding	prior	to	the	next	dose.	For	Cohort	2	(n=7	males,	n=6	females),	mice	were	 treated	as	above,	but	blood	was	drawn	 immediately	 following	each	session	 to	examine	the	levels	of	nicotine	metabolites.	After	re-establishing	baseline	responding,	mice	were	 then	 injected	with	 bupropion,	 or	 vehicle	 control,	 20	minutes	 prior	 to	 each	 session	utilizing	 a	 within	 subject	 Latin-square	 design.	 In	 between	 each	 bupropion	 or	 vehicle	administration	session,	 subjects	were	provided	baseline	days	 to	ensure	stable,	 reinstated	responding	prior	 to	 the	next	dose.	Catheters	were	 flushed	daily	with	physiological	sterile	saline	 solution	 (0.9%	 w/v)	 containing	 heparin	 (100	 units/mL).	 Catheter	 integrity	 was	verified	 with	 the	 ultra	 short-acting	 barbiturate	 anesthetic	 Brevital	 (2%,	 methohexital	sodium,	 Eli	 Lilly,	 Indianapolis,	 IN)	 at	 the	 end	 of	 the	 study.	 Behavioral	 responses	 were	automatically	recorded	by	MedAssociates	software.	In	summary,	the	experimental	timeline	was	as	follows:	Food	self-administration	(5+	days)	à	 intravenous	 surgery	 and	 recovery	 (3+	 days)	à	 nicotine	 self-administration:	acquisition	at	the	0.03	mg/kg/infusion	dose	(8	days)	à	self-administration	of	the	moderate	0.1	mg/kg/infusion	 nicotine	 dose	 (6	 days)	à	 1st	 DLCI-1	 dose	 session	 (vehicle,	 25	 or	 50	
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mg/kg	 according	 to	 Latin-square	 design,	 prior	 to	 the	 self-administration	 session),	immediately	 followed	by	 either	 a	 locomotor	 test	 (cohort	 1)	 or	 blood	draw	 (cohort	 2)	à	baseline	self-administration	(2+	days)	à	2nd	DLCI-1	dose	session,	immediately	followed	by	either	a	locomotor	test	(cohort	1)	or	blood	draw	(cohort	2)	à	baseline	self-administration	(2+	 days)	à	 3rd	 DLCI-1	 dose	 session,	 immediately	 followed	 by	 either	 a	 locomotor	 test	(cohort	 1)	 or	 blood	 draw	 (cohort	 2)	à	 Cohort	 1	 end.	 Cohort	 2	mice	 then	 proceeded	 to:	baseline	self-administration	(2+days)	à	1st	bupropion	dose	session	(vehicle,	1	or	75	mg/kg	according	to	Latin-square	design,	prior	to	the	self-administration	session)	à	baseline	self-administration	(2+days)	à	2nd	bupropion	dose	session	à	baseline	self-administration	(2+	days)	à	 3rd	 bupropion	 dose	 session.	 One	 female	 developed	 a	 leaky	 catheter	 during	 the	bupropion	dosing,	so	she	was	removed	and	two	additional	females	were	assessed	only	with	bupropion	to	achieve	sufficient	subject	numbers.		
Ultra-pressure	liquid	chromatography	(UPLC)-mass	spectrometry	(MS)	Immediately	following	the	self-administration	session,	blood	samples	were	collected	from	the	mice	via	the	facial	vein,	placed	into	a	microcentrifuge	tube	with	20	μl	of	EDTA	(500mM,	pH	8.0)	on	ice,	and	centrifuged	at	3,000	x	g	for	20	minutes	at	4°C.	Plasm	serum	was	collected	and	stored	at	-80°C.	All	blood	samples	were	analyzed	at	the	same	time	with	UPLC-MS.	A	6	μl	aliquot	 of	 each	 plasma	 sample	 was	 spiked	 with	 6	 μl	 of	 a	 mixture	 of	 deuterium-labeled	internal	 standards,	 which	 included	 nicotine-methyl-D3,	 cotinine-methyl-D3	 and	 trans-3′-hydroxycotinine-methyl-D3,	each	at	a	concentration	of	1	ppm.	Fifty	μl	of	100	%	LC-MS	grade	methanol	 was	 added	 to	 precipitate	 out	 proteins.	 After	 vortexing	 and	 subsequent	centrifugation	at	16,000	g	for	15	min	at	4°C,	35	μl	of	supernatant	was	transferred	to	a	sample	
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vial	for	analysis	by	ultra-pressure	liquid	chromatography	(UPLC)-mass	spectrometry	(MS)	analysis.	 UPLC-MS/MS	 Conditions:	 Plasma	 samples	 prepared	 as	 described	 above	 were	analyzed	using	an	ABSciex	6500	LC-MS/MS	system	(Sciex,	Framingham,	MA),	consisting	of	an	LC-30AD	UPLC	pump,	a	SIL30	AC	auto	sampler,	an	ACQUITY	UPLC	BEH	HILIC	(2.1	mm	×	100	 mm,	 1.7	 μm	 particle	 size;	 Waters	 Corp.)	 column	 at	 40°C,	 and	 a	 tandem	 mass	spectrometer	(QTrap	6500).	Ultra-pressure	liquid	chromatography	(UPLC)	was	performed	at	a	flow	rate	of	0.4	ml/min	using	the	following	conditions:	1.5	min	in	15%	solvent	A,	a	linear	gradient	for	1	min	to	50%	solvent	A,	3	min	in	50%	solvent	A,	followed	by	a	return	to	15%	solvent	A	for	2.5	min;	where	solvent	A	is	5	mM	NH4AC	(pH	6.7)	and	50%	acetonitrile	(v/v),	and	solvent	B	is	5	mM	NH4AC	(pH	6.7)	and	90%	acetonitrile	(v/v).	The	injection	volume	of	each	plasma	sample	was	2	μL.	The	QTrap	6500	tandem	mass	spectrometer	was	equipped	with	 an	 electrospray	 ionization	 probe	 operated	 in	 the	 positive-ion	 mode.	 The	 mass	spectrometer	 was	 operated	 in	 the	 multiple	 reaction	 monitoring	 mode	 and	 the	concentrations	 of	 all	 analytes	 were	 determined	 simultaneously	 under	 the	 following	conditions:	 cotinine	 m/z	 177.1>98,	 cotinine-methyl-D3	 m/z	 180.1>101,	 trans-3′-hydroxycotinine	(3HC)	m/z	193.1>80,	and	3HC-methyl-D3	m/z	196.1>80.	A	collision	energy	of	27	V	was	used	for	cotinine	and	cotinine-methyl-D3,	and	32	V	for	3HC	and	3HC-methyl-D3.	A	dwell	time	of	100	msec	was	used	for	all	analytes,	as	well	as	an	ion-spray	voltage	of	5500	V,	an	ion	source	gas	flow	of	50,	DP	of	30	V,	EP	of	10	V,	CXP	of	10	V	and	source	temperature	of	450°C.	Standard	curves	were	constructed	by	plotting	the	ratio	of	analyte	peak	area	to	peak	area	of	the	corresponding	internal	standard	(described	above)	versus	analyte	concentration	for	 eight	 analyte	 concentrations.	 Standards	 at	 concentrations	 ranging	 from	 0.3	 pg/µL	 to	325.5	pg/µL	were	used	to	establish	standard	curves.	Plasma	analyte	concentrations	were	
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determined	 by	measuring	 the	 peak	 area	 ratios	 of	 analyte	 to	 internal	 standard	 and	 then	calculating	 analyte	 concentration	 from	 the	 appropriate	 standard	 curve	 using	MultiQuant	2.1.1	 software.	 The	 quantification	 limits	 (signal/noise>10)	 for	 each	 compound	 were	 0.3	pg/µL	for	cotinine	and	0.6	pg/µL	for	3HC.	
	
Open	field	locomotor	test	The	open	field	chamber	was	composed	of	Plexiglas	(35	cm	L	×	35	cm	W	×	31	cm	H)	as	described	previously	(Chen	et	al.,	2018b).	Following	testing	in	the	intravenous	nicotine	self-administration	session,	mice	(Cohort	1,	n=5)	were	immediately	transferred	to	the	open	field	chamber.	 After	 a	 5-minute	 habituation	 period,	 subjects	 were	 scored	 in	 the	 open	 field	apparatus	for	a	15-minute	session	to	assess	locomotor	activity.	Activity	was	recorded	with	a	video	 camera	 and	 distance	 travelled,	 time	 mobile	 and	 center	 time	 were	 scored	 by	 two	experimenters	blinded	to	the	group	condition	with	ANY-Maze	Software	(Stoelting	Co.,	Wood	Dale,	IL,	USA).	
	
Operant	food	training		Subjects	(n=11	males)	were	mildly	food	restricted	to	85-90%	of	free	feeding	weight	and	trained	to	press	a	lever	in	an	operant	chamber	(Med	Associates,	Fairfax,	VT,	USA)	for	food	pellets	(20	mg;	TestDiet)	up	to	a	fixed-ratio	5,	time	out	20	s	(FR5TO20s)	schedule	of	reinforcement,	 as	 previously	 described	 (Fowler	 and	 Kenny,	 2011).	 Each	 session	 was	performed	 using	 2	 retractable	 levers	 (1	 active,	 1	 inactive).	 Completion	 of	 the	 response	criteria	on	the	active	lever	resulted	in	the	delivery	of	a	food	pellet.	Responses	on	the	inactive	lever	 were	 recorded	 but	 had	 no	 scheduled	 consequences.	 Once	 stable	 responding	 was	
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achieved	 (criteria	 >30	 pellets	 per	 session	 across	 3	 consecutive	 sessions),	 subjects	 were	administered	DLCI-1,	or	vehicle	control,	30	minutes	prior	to	the	session	utilizing	a	within	subject,	cross-over	design.	Subjects	were	provided	at	least	one	baseline	day	in	between	test	sessions	 to	 ensure	 stable	 responding	prior	 to	 the	next	 injection	 in	 the	 series.	Behavioral	responses	were	automatically	recorded	by	MedAssociates	software.			
Statistical	analyses	Data	were	analyzed	by	a	 t-test,	 one-way	or	 two-way	ANOVA,	 as	 appropriate,	with	Prism	software	(GraphPad,	La	Jolla,	CA,	USA).	Significant	main	or	 interaction	effects	were	followed	 by	 Bonferroni	 post-hoc	 comparison	 with	 correction	 for	 multiple	 comparisons.	Statistical	 reporting	 for	 ANOVAs	 are	 presented	 as	 a	 F-statistic	 value:	 F(degrees	 of	 freedom	 for	
group/treatment	number,	degrees	of	freedom	for	subject	number)	=	test	value.	The	criterion	for	significance	was	set	at	α=0.05.		
RESULTS	
Decreased	nicotine	self-administration	with	administration	of	DLCI-1	Mice	were	 examined	 for	 the	 effects	 of	 DLCI-1	 (Fig	 1A)	 or	 vehicle	 on	 intravenous	nicotine	self-administration.	Since	nicotine	 is	mainly	metabolized	by	CYP2A6	 in	 the	 liver,	DLCI-1	or	vehicle	was	administered	via	oral	gavage	to	allow	for	first	pass	absorption	and	thus	more	directed	targeting	to	this	organ.	Administration	of	the	25	and	50	mg/kg	doses	of	DLCI-1	 effectively	 reduced	 the	 number	 of	 nicotine	 infusions	 earned	 compared	 to	 vehicle	control	in	both	males	(Fig	1B)	(repeated	measures	one-way	ANOVA,	F(2,18)	=	25.31,	p	<	0.0001)	and	females	(Fig	1D)	(repeated	measures	one-way	ANOVA,	F(2,10)	=	9.88,	p	=	0.0043).	In	the	
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post-hoc	tests,	both	the	25	mg/kg	and	50	mg/kg	doses	resulted	in	significantly	lower	rates	of	responding	than	vehicle	control	for	males	(p	<	0.0001)	and	females	(p	<	0.05	vehicle	vs.	25	mg/kg,	p	<	0.01	vehicle	vs.	50	mg/kg).	To	assess	the	level	of	lever	pressing	behavior,	the	number	of	active	and	inactive	lever	presses	were	also	examined,	and	statistically	significant	differences	were	established	for	the	active	 lever	across	conditions	in	both	males	(Fig	1C)	(repeated	measures	two-way	ANOVA,	dose	F(2,18)=	18.36,	p	<	0.0001;	lever	F(1,9)	=	39.76,	p	=	0.0001;	interaction	F(2,18)	=	22.33,	p	<	0.0001)	and	females	(Fig	1E)	(repeated	measures	two-
way	ANOVA,	dose	F(2,10)=	6.20,	p	=	0.0177;	lever	F(1,5)	=	13.90,	p	=	0.0136;	interaction	F(2,10)	=	13.83,	 p	 =	 0.0013).	 Specifically,	 the	 vehicle	 injection	 resulted	 in	 a	 significantly	 greater	number	of	active	lever	responses	than	both	the	25	mg/kg	and	50	mg/kg	doses	for	both	males	(post	hoc,	Active	0	vs	25	p<0.0001,	Active	0	vs	50	p<0.0001)	and	females	(post	hoc,	Active	0	vs	25	p<0.001,	Active	0	vs	50	p<0.001).	Significant	differences	were	not	found	in	the	rate	of	responding	 on	 the	 inactive	 levers.	 Together,	 these	 findings	 demonstrate	 that	 DLCI-1	effectively	 reduced	 nicotine	 intake,	 without	 affecting	 general	 non-specific	 inactive	 lever	pressing	behavior.		Blood	 samples	 were	 collected	 after	 nicotine	 self-administration	 with	 DLCI-1	treatment	 to	 examine	 the	 levels	 of	 nicotine’s	 main	 metabolite,	 cotinine,	 which	 is	 then	metabolized	 into	 3HC.	 If	 mice	 titrate	 their	 nicotine	 levels	 to	 maintain	 a	 similar	 level	 of	activation	 of	 neural	 nAChRs	 across	 treatments,	 one	 would	 predict	 that	 the	 level	 of	 the	metabolites	 would	 be	 relatively	 lower	 with	 inhibitor	 treatment	 across	 groups,	 despite	differences	in	nicotine	intake.	This	supposition	considers	the	fact	that	each	intravenous	self-administration	session	varies	in	the	pattern	of	nicotine	infusions	across	time	and	amount	of	nicotine	 administered,	 dependent	 on	 the	 animal’s	 volitional	 behavior,	 which	 may	 also	
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introduce	the	possibility	of	allowing	for	accumulation	of	nicotine	with	DLCI-1	treatment	and	thus	 similar	 levels	 of	 metabolites	 at	 the	 session	 end.	 Considerations	 must	 also	 be	incorporated	for	differences	in	the	rate	of	elimination	of	metabolites	throughout	the	hour	session	duration	via	excretion	from	the	body,	with	earlier	infusions	during	the	session	likely	resulting	 in	greater	excretion	of	metabolites	prior	 to	blood	collection.	Given	 this,	we	also	analyzed	 the	 pattern	 of	 nicotine	 intake	 across	 treatment	 conditions	 to	 evaluate	 the	 time	course	of	nicotine	exposure	 for	each	treatment.	 In	males	(Fig	2A),	cotinine	 levels	did	not	differ	between	the	vehicle	and	25	mg/kg	treatment	(paired	t-test,	t(6)	=	1.506,	p	=	0.0913)	or	50	mg/kg	 treatment	 (paired	 t-test,	 t(5)	 =	0.566,	p	=	0.2979).	 In	 contrast,	 3HC	 levels	were	higher	with	 vehicle	 compared	 to	 the	 25	mg/kg	 treatment	 (paired	 t-test,	 t(6)	 =	 2.816,	 p	 =	0.0153),	but	no	differences	were	found	between	the	vehicle	and	50	mg/kg	treatment	(paired	
t-test,	t(5)	=	1.608,	p	=	0.0844).	When	examining	nicotine	intake	across	the	15	min	intervals	of	the	session,	the	vehicle	condition	maintained	a	consistently	higher	level	of	nicotine	intake	across	the	session,	which	was	approximately	twice	that	of	the	DLCI-1	treatments	(Fig	2B).	In	females	(Fig	2C),	cotinine	levels	were	statistically	lower	with	both	the	25	mg/kg	treatment	(paired	t-test,	t(5)	=	2.465,	p	=	0.0284)	and	50	mg/kg	treatment	(paired	t-test,	t(5)	=	3.101,	p	=	0.0134),	as	compared	to	the	vehicle.	For	3HC,	differences	were	not	found	between	the	vehicle	and	25	mg/kg	treatment	(paired	t-test,	t(5)	=	1.768,	p	=	0.0687),	but	the	50	mg/kg	treatment	led	to	 lower	3HC	 levels	 than	the	vehicle	condition	(paired	t-test,	 t(5)	=	4.670,	p	=	0.0027).	When	examining	nicotine	intake	within	the	hour	session	in	females,	all	conditions	displayed	a	 slight	 downward	 trajectory	 in	 nicotine	 consumption	 (Fig	 2D).	 Taken	 together,	 these	findings	 are	 indicative	 of	 a	 dynamic	 process	 of	 intake,	 metabolism	 and	 elimination	 for	nicotine	and	its	metabolites	throughout	the	self-administration	session.	
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Bupropion-induced	decrease	in	nicotine	self-administration		 To	 further	 support	 the	 potential	 of	DLCI-1	 as	 a	 tobacco	 cessation	 therapeutic,	we	assessed	the	effects	of	bupropion	on	nicotine	intake	for	comparison	purposes.	Interestingly,	the	 effects	 of	 bupropion	 on	 nicotine	 self-administration	 in	mice	 has	 not	 been	 previously	investigated.	Thus,	we	examined	the	impact	of	a	moderate	(1	mg/kg)	and	high	(75	mg/kg)	bupropion	dose;	in	the	rodent	literature,	the	doses	of	bupropion	range	from	0.1	to	78	mg/kg	(Rauhut	et	al.,	2003;	Rauhut	et	al.,	2008;	Damaj	et	al.,	2010;	Grabus	et	al.,	2012;	Hall	et	al.,	2015).	 The	 1mg/kg	 dose	 was	 selected	 based	 on	 prior	 findings	 that	 this	 dose	 abolishes	nicotine	 reward	 in	 the	 conditioned	 place	 preference	 paradigm	 and	 reverses	 nicotine-induced	tolerance	in	mice	(Damaj	et	al.,	2010;	Grabus	et	al.,	2012).	The	high	75	mg/kg	dose	was	selected	since	this	dose	range	has	been	shown	to	attenuate	nicotine	self-administration	in	rats	in	several	prior	studies	(Rauhut	et	al.,	2003;	Rauhut	et	al.,	2008;	Hall	et	al.,	2015).	In	males,	we	found	a	significant	difference	between	treatments	(Fig	3A)	(repeated	measures	
one-way	ANOVA,	F(2,8)	=	8.249,	p	=	0.0114).	Post-hoc	analyses	revealed	that	the	high	dose	(75	mg/kg),	but	not	 the	moderate	 (1	mg/kg)	dose,	 induced	a	 significant	decrease	 in	nicotine	intake	 compared	 to	 the	 vehicle	 (p	 <	 0.01).	 However,	 it	 is	 important	 to	 note	 that	 during	testing,	the	mice	exhibited	an	adverse	behavioral	state	following	the	high	dose	bupropion	injection,	with	behaviors	representative	of	withdrawal	-	shaking,	hunched	posture,	gnawing,	lethargy,	and	piloerection.	As	a	quantitative	measure,	we	examined	the	latency	for	the	mice	to	 receive	 their	 first	nicotine	 infusion	during	 the	session,	which	provides	evidence	of	 the	ability	of	the	mice	to	ambulate	around	the	testing	chamber	and	press	the	lever.	It	is	expected	that	subjects	should	attenuate	their	responding	 for	nicotine	with	a	 therapeutic	 treatment	
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after	experiencing	the	interactive	effects	of	the	therapeutic	with	the	first	nicotine	infusion;	thus,	subjects	would	not	be	expected	to	differ	in	the	initial	latency	to	first	reward.	However,	we	 found	 a	 significant	 increase	 in	 the	 latency	 with	 the	 75	 mg/kg	 high	 dose	 bupropion	treatment,	 but	 not	 for	 any	 other	 treatment	 condition	 with	 either	 DLCI-1	 or	 bupropion,	thereby	providing	evidence	of	the	negative	behavioral	state	of	the	male	mice	following	the	high	 bupropion	 dose	 (Fig	3B)	 (One-way	ANOVA,	 F(5,42)	=	 21.05,	 p	 <	 0.0001;	 post-hoc	 p	 <	0.0001for	all	conditions	compared	to	75	mg/kg	bupropion).	In	females,	bupropion	at	both	doses	resulted	in	a	statistically	significant	decrease	in	nicotine	intake	relative	to	the	vehicle	(Fig	3C)	(repeated	measures	one-way	ANOVA,	F(2,12)	=	20.02,	p	=	0.0002;	post-hoc:	vehicle	vs.	1	mg/kg,	p	<	0.05;	vehicle	vs.	75	mg/kg:	p	<	0.0001).	At	the	high	75	mg/kg	bupropion	dose,	similar	adverse	behavioral	effects	were	noted	in	the	females,	which	was	further	confirmed	with	 analysis	 of	 the	 latency	 to	 first	 nicotine	 infusion	 among	 DLCI-1	 and	 bupropion	treatments	(Fig	3D)	(One-way	ANOVA,	F(5,33)	=	5.863,	p	=	0.0006;	post-hoc	p	<	0.05	for	all	conditions	compared	to	75	mg/kg	bupropion).			
No	differences	in	food	responding	with	administration	of	DLCI-1	To	further	verify	 that	 the	differences	 found	with	nicotine	self-administration	were	selective	to	nicotine	consumption,	we	examined	the	effects	of	DLCI-1	on	operant	responding	for	 food	pellets	under	 the	 same	 fixed	 ratio	5,	 time	out	20	 sec	 schedule	of	 reinforcement.	Separate	cohorts	of	male	mice	were	examined	for	the	25	mg/kg	and	50	mg/kg	doses.	At	the	25	mg/kg	dose,	 subjects	did	not	differ	 in	 the	amount	of	 food	pellets	earned	compared	 to	vehicle	control	 (Fig	4A)	 (paired	 t-test,	 t(4)	=	0.794,	p	=	0.4716),	nor	did	 they	differ	 in	 the	number	of	active	or	inactive	lever	presses	between	injection	conditions	(Fig	4B)	(repeated	
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measures	 two-way	 ANOVA,	 dose	 F(1,4)=	 0.549,	 p	 =	 0.4996;	 lever	F(1,4)	=	 53.06,	 p	 =	 0.0019;	
interaction	F(1,4)	=	0.662,	p	=	0.4616).	Similarly,	subjects	did	not	differ	at	the	50	mg/kg	dose	in	either	food	responding	(Fig	4C)	(paired	t-test,	t(5)	=	1.416,	p	=	0.2159)	or	in	the	number	of	active	or	 inactive	 lever	presses	 (Fig	4D)	 (repeated	measures	 two-way	ANOVA,	dose	 F(1,5)=	2.525,	p	=	0.1729;	lever	F(1,5)	=	339.6,	p	<	0.0001;	interaction	F(1,5)	=	2.093,	p	=	0.2076).	These	data	provide	evidence	that	DLCI-1	does	not	affect	lever	pressing	behavior	for	food	reward	or	general	non-specific	inactive	lever	pressing	behavior.		
Effects	of	DLCI-1	induced	lowering	of	nicotine	intake	on	nicotine-mediated	locomotion	Nicotine	has	been	demonstrated	to	exert	hyperlocomotive	or	hypolocomotive	effects	at	low	or	high	doses,	respectively.	Thus,	following	the	nicotine	session	with	the	higher	50	mg/kg	dose	or	vehicle	control,	mice	were	immediately	transferred	to	open	field	chambers	to	examine	for	differences	in	locomotion.	This	assessment	serves	as	a	secondary	measure	of	DLCI-1’s	nicotine-mediated	effects	with	the	decreased	self-administered	nicotine	level.	The	mice	consumed	significantly	less	total	nicotine	(mg	per	kg)	within	each	self-administration	session	(Fig	5A)	(paired	t-test,	t(4)	=	3.774,	p	=	0.0098).	However,	they	did	not	differ	in	the	total	distance	travelled	within	the	open	field	(Fig	5B)	(paired	t-test,	t(4)	=	0.969,	p	=	0.3874)	or	 in	the	total	 time	mobile	(Fig	5C)	 (paired	t-test,	 t(4)	=	0.433,	p	=	0.6871).	Further,	since	decreased	time	in	the	center	of	an	open	field	has	been	proposed	to	be	a	correlate	of	increased	anxiety	and	nicotine	has	been	shown	to	mediate	anxiolytic	behavioral	effects,	the	duration	of	 center	 time	 was	 assessed	 to	 provide	 an	 initial	 examination	 of	 an	 anxiety-associated	response.	However,	the	mice	did	not	differ	in	the	amount	of	time	spent	in	the	center	of	the	open	field	(Fig	5D)	(paired	t-test,	t(4)	=	0.185,	p	=	0.8622).	These	findings	indicate	that	DLCI-
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1	decreases	nicotine	intake,	and	in	doing	so,	results	in	similar	nicotine-mediated	behavioral	actions	 with	 locomotion.	 Together,	 this	 provides	 evidence	 of	 inhibition	 of	 nicotine	metabolism	with	similar	in	vivo	actions	of	nicotine	between	conditions.	Moreover,	the	food	training	and	locomotor	data	also	support	the	contention	that	DLCI-1	does	not	 induce	any	adverse	behavioral	effects	at	the	doses	administered.		
DISCUSSION	In	these	studies,	we	found	that	oral	administration	of	DLCI-1,	a	potent,	selective	and	metabolically	 stable	 CYP2A6	 inhibitor,	 results	 in	 decreased	 intravenous	 nicotine	 self-administration	in	both	male	and	female	mice.	Throughout	the	self-administration	session,	the	mice	appeared	to	consistently	titrate	their	intake	across	the	15	min	session	intervals.	In	males,	this	resulted	in	the	detection	of	similar	levels	of	nicotine’s	metabolites,	cotinine	and	3HC,	in	the	blood,	with	the	exception	of	less	3HC	found	following	the	25	mg/kg	dose	of	DLCI-1.	In	contrast,	females	tended	to	adjust	their	responding	downward	throughout	the	session,	and	this	resulted	in	significantly	less	cotinine	and	3HC	after	the	self-administration	session	with	 the	 DLCI-1	 treatments	 compared	 to	 vehicle.	 Interestingly,	 DLCI-1	 induced	 an	approximate	50%	decrease	on	nicotine	intake	in	both	males	and	females,	which	was	much	greater	than	one	of	the	first-line	therapeutics	for	tobacco	cessation,	bupropion,	at	a	moderate	dose.	 Further,	 the	 decrease	 in	 nicotine	 intake	 in	 the	 presence	 of	 DLCI-1	 led	 to	 a	 similar	locomotor	effect	as	that	found	with	higher	levels	of	nicotine	intake	under	vehicle	conditions,	supporting	 the	 contention	 that	 similar	 levels	 of	 nAChR	 activation	 in	 the	 brain	 occurred	despite	 decreased	 levels	 of	 nicotine	 intake	with	DLCI-1	 treatment.	Of	 further	 note,	 these	effects	were	specific	to	 lever	pressing	for	nicotine	reward,	as	differences	 in	 inactive	 lever	
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pressing	behavior	or	 food	self-administration	were	not	 found.	Taken	together,	 these	data	support	 the	 conclusion	 that	 the	novel	 CYP2A6	 enzyme	 inhibitor,	DLCI-1,	 has	 therapeutic	potential	 to	 selectively	 reduce	 tobacco	 and	 nicotine	 consumption	 and	 thereby	 promote	smoking	cessation.		 The	foundation	for	these	studies	is	based	on	findings	in	humans	with	CYP2A6	allelic	variation	 and	 prior	 reports	with	methoxsalen,	 in	which	 lower	 levels	 of	 CYP2A6	 nicotine	metabolism	has	been	associated	with	decreased	nicotine	intake	and	dependence	(Sellers	et	al.,	2000;	Strasser	et	al.,	2007;	Patterson	et	al.,	2008;	Rodriguez	et	al.,	2011;	Liakoni	et	al.,	2019).	Methoxsalen	 is	 classified	as	a	mechanism-based	 inhibitor;	 the	drug	 itself	becomes	metabolically	activated	by	CYP2A6,	leading	to	an	active	metabolite	that	irreversibly	binds	to	CYP2A6	 and	 inhibits	 its	 activity	 (Blobaum,	 2006).	 In	 addition,	 several	 studies	 in	 mouse	models	 have	 provided	 further	 support	 for	 methoxsalen’s	 potential	 in	 reducing	 nicotine	dependence	 associated	 behaviors	 (Alsharari	 et	 al.,	 2014;	 Bagdas	 et	 al.,	 2014).	 However,	besides	its	actions	on	CYP2A6,	methoxsalen	also	has	carcinogen	effects	when	combined	with	UV	longwave	radiation,	and	this	has	thereby	limited	its	potential	for	further	development	as	a	smoking	cessation	therapeutic.	In	contrast,	DLCI-1	was	developed	as	a	structural	analogue	of	 nicotine,	 as	 such,	DLCI-1	 ascended	 from	 a	 lead	 directed,	medicinal	 chemical	 synthesis	program	with	the	highest	CYP2A6	potency	(0.017	µM)	of	any	inhibitor	tested,	to	date,	with	high	 selectivity	 ratios	 (IC50(CYPXXX)/IC50(CYP2A6))	 toward	 all	 other	 human	drug	metabolizing	CYPs	ranging	from	>760	for	CYP3A4	to	>5	for	CYP2B6,	and	good	human	liver	microsomal	half-life	(40	min).	Further,	the	compound	falls	within	the	boundaries	of	Lipinski’s	rule	of	five:	calculated	 octanol-water	 partition	 coefficient	 (cLogP)	 =	 2.108,	MW	=	 218.32,	 topological	
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polar	surface	area	(tPSA)	=	38.38,	number	of	hydrogen	bond	donors	=	1,	number	of	hydrogen	bond	acceptors	=	2	(Denton	et	al.,	2018).	Although	the	compound	was	designed	to	selectively	inhibit	CYP2A6,	 the	possibility	of	DLCI-1	 to	enter	 the	brain	by	diffusing	across	 the	blood	brain	barrier	may	occur,	which	will	need	to	be	addressed	in	future	studies.			 It	is	of	further	note	that	the	current	studies	were	conducted	in	a	mouse	model	system.	Since	 rats	 metabolize	 nicotine	 primarily	 with	 CYP2B1,	 limitations	 are	 imposed	 when	attempting	to	translate	findings	from	rats	to	human	hepatic	function	(Matta	et	al.,	2007).	In	contrast,	the	mouse	isoform	CYP2A5	is	homologous	to	human	CYP2A6,	allowing	for	a	more	relatable	 foundation	for	 future	clinical	development.	Further,	 it	should	also	be	noted	that	DLCI-1	was	dosed	orally	based	on	two	considerations.	First,	given	that	nicotine	 is	mainly	metabolized	in	the	periphery	by	the	liver,	this	allowed	us	to	take	advantage	of	the	first	pass	effect	found	with	gastrointestinal	absorption,	in	which	drug	uptake	occurs	via	the	portal	vein	into	 hepatic	 circulation.	 Second,	 this	 route	 of	 administration	 provides	 translational	relevance	to	future	studies	since	oral	administration	is	preferred	for	human	dosing.			 Interestingly,	males	and	females	demonstrated	a	similar	effectiveness	with	DLCI-1’s	ability	 to	 reduce	 nicotine	 self-administration,	 as	 both	 sexes	 exhibited	 a	 decrease	 in	 the	number	of	nicotine	infusions	and	reduction	of	active	lever	presses	with	treatment.	Thus,	this	effect	was	notably	robust	in	consideration	of	the	increased	variability	in	responding	typically	found	 in	 female	mice	 with	 intravenous	 nicotine	 self-administration.	When	 assessing	 the	amount	of	nicotine	self-administered	relative	to	nicotine’s	metabolites,	differences	with	the	DLCI-1	treatment	were	not	consistent	between	sexes,	which	may	be	attributed	to	several	
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factors.	 First,	 one	must	 consider	 the	 fast	 metabolism	 of	 nicotine	 in	 mice	 relative	 to	 the	session	duration.	Whereas	humans	exhibit	a	nicotine	half-life	(t1/2)	of	~2	hours,	the	plasma	nicotine	metabolism	of	mice	is	estimated	to	be	6-7	min	(Matta	et	al.,	2007).	In	consideration	of	 this	 time	 frame,	 the	measurements	 in	 the	 current	 study	 reflect	 a	 dynamic	 process	 of	varying	 intravenous	 nicotine	 infusions	 (dependent	 on	 the	 mouse’s	 volitional	 behavior),	metabolism	and	excretion	throughout	the	one	hour	session,	given	that	blood	samples	were	collected	at	the	session	end.	Second,	the	rate	of	nicotine	metabolism	has	been	shown	to	differ	between	 males	 and	 females.	 Specifically,	 females	 have	 been	 found	 to	 metabolize	 both	nicotine	and	 cotinine	 faster	 than	males	 (Matta	 et	 al.,	 2007;	Benowitz	 et	 al.,	 2009).	 In	 the	current	 study,	 females	 exhibited	more	 pronounced	 changes	 in	 nicotine	metabolite	 levels	with	the	treatment-induced	differences	in	nicotine	self-administration,	which	is	consistent	with	 the	 prior	 findings.	 Third,	 chronic	 cigarette	 exposure	 has	 been	 shown	 to	 lead	 to	decreased	nicotine	clearance	in	humans	(Benowitz	and	Jacob,	1994;	Benowitz	et	al.,	2009),	although	it	is	unknown	as	to	whether	this	can	be	attributed	to	nicotine	alone	(e.g.,	as	opposed	to	other	 constituents	 in	 tobacco	 smoke)	 and	whether	mice	develop	 similar	 changes	with	chronic	exposure.	Even	so,	given	that	the	mice	in	the	current	study	were	chronically	self-administering	nicotine	for	at	least	13	days	prior	to	the	DLCI-1	dosing	schedule,	our	findings	support	the	effectiveness	of	DLCI-1	as	a	potential	therapeutic	consistent	with	intervention	after	long-term	nicotine	exposure.			In	an	attempt	 to	provide	a	 correlate	 to	 the	potential	 effectiveness	of	DLCI-I	 compared	 to	other	nicotine	cessation	therapeutics,	we	examined	the	effects	of	bupropion	on	intravenous	nicotine	 self-administration	 in	 mice,	 which	 has	 not	 been	 previously	 investigated	 in	 the	
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mouse	 model.	 While	 the	 1	 mg/kg	 bupropion	 dose	 has	 been	 shown	 to	 block	 nicotine’s	rewarding	effects	 in	 the	conditioned	place	preference	paradigm	(Damaj	et	al.,	2010),	 this	dose	was	ineffective	in	altering	nicotine	self-administration	in	male	mice,	while	the	female	mice	 exhibited	 a	 slight	 decrease	 in	 responding	 at	 this	 dose.	 Thus,	 comparing	 the	 ~50%	decrease	 in	 nicotine	 intake	 found	 with	 DLCI-1	 to	 this	 dose	 of	 bupropion,	 the	 evidence	suggests	that	DLCI-1	would	be	more	efficacious.	However,	since	studies	in	rats	have	used	a	much	higher	bupropion	dose,	we	also	examined	the	effects	of	a	75	mg/kg	dose.	While	both	males	 and	 females	 exhibited	 a	 substantial	 decrease	 in	 the	 number	 of	 nicotine	 infusions	earned,	 these	 effects	were	 likely	 secondary	 to	 general	 behavioral	 inhibition	 and	malaise,	since	the	mice	receiving	the	high	dose	exhibited	adverse	health-related	effects	(e.g.,	shaking,	lethargy,	 gnawing,	piloerection,	hunched	posture).	This	behavioral	 inhibition	was	 further	confirmed	by	examining	the	latency	to	respond	for	the	first	nicotine	infusion,	in	which	mice	treated	with	75	mg/kg	bupropion	exhibited	a	substantial	delay	in	pressing	the	lever	for	the	first	 infusion	 compared	 to	 all	 other	doses	 for	both	DLCI-1	 and	bupropion.	Moreover,	 the	behavioral	characteristics	evidenced	in	the	mice	at	this	high	dose	are	consistent	with	that	found	 in	 humans	 with	 bupropion	 overdose	 (Stall	 et	 al.,	 2014).	 Interestingly,	 doses	 of	bupropion	in	the	intermediate	range	lead	to	increased,	rather	than	decreased,	nicotine	self-administration	in	rats	(Rauhut	et	al.,	2003).	Thus,	taken	together,	these	findings	support	the	contention	 that	 DLCI-1	 may	 serve	 as	 an	 effective	 therapeutic	 to	 promote	 tobacco	 and	nicotine	cessation.		 In	 addition	 to	 the	 effectiveness	 on	 addiction-related	 processes,	 CYP2A6	 inhibitors	may	 also	 be	 relevant	 to	 tobacco-	 and	 nicotine-associated	 disease.	 For	 instance,	
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polymorphism	in	the	CYP2A6	gene	rendering	an	absence	of	CYP2A6	metabolic	function	leads	to	 decreased	 tobacco	 use	 and	 lung	 cancer	 risk	 (Ariyoshi	 et	 al.,	 2002).	 Conversely,	 an	interaction	between	allelic	variation	 in	the	CHRNA5-CHRNA3-CHRNB4	gene	cluster,	which	encode	the	a5,	a3,	and	b4	nAChR	subunits,	respectively,	and	normal	CYP2A6	metabolism	was	found	to	increase	risk	for	lung	cancer,	an	effect	that	was	interestingly	found	with	both	high	 and	 lower	 (e.g.,	 <20	 cigarettes	per	day)	nicotine	 exposure	 (Wassenaar	 et	 al.,	 2011).	Therefore,	the	resulting	effects	of	CYP2A6	inhibition	may	serve	to	mitigate	lung	cancer	risk	in	patients	based	on	enzymatic	levels	and	genetic	predisposition.			 In	conclusion,	the	novel	CYP2A6	inhibitor,	DLCI-1,	is	a	promising	CYP2A6	inhibitor,	which	 was	 rationally	 designed	 to	 decrease	 nicotine	 intake.	 Our	 data	 provide	 the	 first	evidence	 that	 DLCI-1	 effectively	 attenuates	 intravenous	 nicotine	 self-administration	 in	 a	mouse	 model.	 In	 addition	 to	 reducing	 nicotine	 consumption,	 pharmacological	 CYP2A6	inhibition	may	also	lessen	withdrawal	symptoms	to	further	promote	abstinence	and/or	may	ease	 the	 transition	 to	 achieve	 abstinence	 in	 combination	 with	 nicotine	 replacement	approaches,	 although	 this	needs	 to	be	 further	 investigated.	Taken	 together,	 these	studies	provide	 a	 foundation	 for	 further	 compound	 development	 to	 derive	 a	 highly	 efficacious	therapeutic	to	promote	tobacco,	as	well	as	e-cigarette,	cessation.			
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FIGURE	LEGENDS	
Figure	1.	The	CYP2A6	inhibitor	DLCI-1	decreases	nicotine	self-administration	in	both	
male	and	 female	mice.	Mice	were	 examined	 for	 their	 responding	 to	obtain	 intravenous	nicotine	 infusions	 following	 administration	 of	 DLCI-1	 or	 vehicle	 control.	 (A)	 Chemical	structure	 of	 DLCI-1.	 (B)	 In	 males	 (n=10),	 both	 doses	 of	 DLCI-1	 (25	 and	 50	 mg/kg,	 po)	significantly	decreased	the	number	of	nicotine	infusions	earned	compared	to	vehicle	control.	
(C)	When	the	number	of	lever	presses	were	examined	for	the	nicotine	sessions,	male	mice	exhibited	 a	 significant	 decrease	 in	 the	 number	 of	 active	 lever	 presses	 with	 DLCI-1	pretreatment.	In	contrast,	no	significant	differences	were	found	in	the	number	of	 inactive	lever	 presses.	 (D)	 In	 females	 (n=6),	 DLCI-1	 decreased	 the	 number	 of	 nicotine	 infusions	earned	at	both	doses	(25	and	50	mg/kg,	po)	compared	to	vehicle	control.	(E)	Female	mice	also	 exhibited	 a	 significant	 decrease	 in	 the	 number	 of	 active	 lever	 presses	 with	 DLCI-1	pretreatment,	but	no	in	the	number	of	inactive	lever	presses.		*p<0.05,	**p<0.01,	***p<0.001,	****p<0.0001	as	compared	to	0	mg/kg	vehicle	control.	Data	are	presented	as	mean	±	SEM.			
Figure	2.	Nicotine	metabolites	in	the	blood	following	DLCI-1	treatment	and	nicotine	
self-administration.	Blood	 samples	were	 analyzed	 following	 the	 one	 hour	 nicotine	 self-administration	session	to	examine	for	differences	in	metabolite	levels.	(A)	In	males	(n=7),	despite	a	higher	level	of	nicotine	intake	in	the	vehicle	condition,	the	levels	of	cotinine	did	not	differ	 among	 treatments	 immediately	 after	 the	 session.	 However,	 the	 25	 mg/kg	 DLCI-1	treatment	did	lead	to	decreased	3HC	levels	compared	to	the	vehicle	treatment.	(B)	Analysis	of	the	pattern	of	nicotine	self-administered	(mg/kg)	throughout	the	session	duration	reveals	that	the	males	maintained	a	consistent	level	of	responding	over	each	15	min	interval,	with	consistently	lower	intake	found	with	DLCI-1	treatment.	(C)	In	females	(n=6),	the	25	and	50	
This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on October 18, 2019 as DOI: 10.1124/jpet.119.260653
 at ASPET Journals on November 12, 2019
jpet.aspetjournals.org
Downloaded from 
JPET # 260653 
 36 
mg/kg	DLCI-1	treatment	resulted	in	a	lower	level	of	cotinine,	and	50	mg/kg	DLCI-1	also	led	to	a	significant	decrease	in	3HC,	as	compared	to	the	vehicle	treatment.	(D)	Analysis	of	the	pattern	of	nicotine	self-administered	(mg/kg)	throughout	the	session	duration	 in	 females	reveals	 that	 the	 vehicle	 and	 DLCI-1	 treatments	 led	 to	 consistent	 levels	 of	 responding	 at	higher	and	lower	levels,	respectively,	and	there	was	an	apparent	downward	shift	in	intake	over	the	15	min	intervals.	*p<0.05,	**p<0.01	compared	to	the	0	mg/kg	vehicle	control.		
Figure	3.	Effects	of	bupropion	 treatment	on	nicotine	 self-administration.	Mice	were	examined	 to	 assess	whether	 bupropion	would	 exert	 a	 similar	 reduction	 in	 nicotine	 self-administration	 as	 that	 found	 with	 DLCI-1.	 (A)	 In	 males	 (n=5),	 a	 significant	 decrease	 in	nicotine	 infusions	earned	was	 found	 following	 the	high	 (75	mg/kg),	but	not	moderate	 (1	mg/kg),	 bupropion	 treatment	 as	 compared	 to	 vehicle.	 **p<0.01	 vs.	 0	mg/kg	 vehicle.	 (B)	Males	treated	with	the	high	dose	of	bupropion	(75	mg/kg)	exhibited	significantly	delayed	latency	to	respond	on	the	active	lever	for	the	first	 infusion	of	the	session	compared	to	all	other	 treatment	 conditions,	 indicating	behavioral	 suppression.	 ****p<0.0001	vs.	 all	 other	treatment	 conditions.	 (C)	 In	 females	 (n=7),	 both	 the	 moderate	 (1	 mg/kg)	 and	 high	 (75	mg/kg)	dose	of	bupropion	significantly	attenuated	the	number	of	nicotine	infusions	earned.	****p<0.0001	vs.	0	mg/kg	vehicle.	(D)	Females	administered	the	high	dose	of	bupropion	(75	mg/kg)	had	a	significantly	delayed	latency	to	respond	on	the	active	lever	for	the	first	infusion	of	the	session	compared	to	all	other	treatments,	indicating	behavioral	suppression.	*p<0.05	vs.	all	other	treatment	conditions.	
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Figure	4.	No	differences	 in	 food	self-administration	 following	administration	of	 the	
CYP2A6	inhibitor	DLCI-1.	Mice	were	trained	to	self-administer	food	pellets	and	examined	for	the	effects	of	DLCI-1	pretreatment	on	behavior	(n=5-6/group).	(A-B)	When	pretreated	with	 the	 lower	 dose	 of	 DLCI-1	 (25	mg/kg)	 or	 vehicle	 control,	mice	 did	 not	 differ	 in	 the	number	of	food	pellets	earned	(A)	or	in	the	number	of	active	and	inactive	lever	presses	(B).	
(C-D)	 Pretreatment	with	 the	 higher	 dose	 of	 DLCI-1	 (50	mg/kg)	 also	 did	 not	 induce	 any	differences	in	food	self-administration	behavior	for	the	number	of	pellets	earned	(C),	or	in	the	number	of	active	and	inactive	lever	presses	(D).	Data	are	presented	as	mean	±	SEM.	
	
Figure	5.	Similar	 locomotor	behaviors	with	DLCI-1	pretreatment	despite	decreased	
nicotine	 exposure.	 Following	 the	 intravenous	 nicotine	 self-administration	 session	 with	vehicle	or	50	mg/kg	DLCI-1	 treatment,	male	mice	 (n=5)	were	 immediately	 examined	 for	their	locomotor	behaviors	in	an	open	field.	(A)	During	the	nicotine	session,	DLCI-1	treatment	resulted	in	approximately	half	of	the	amount	of	nicotine	intake	as	that	found	in	the	control	condition.	**p<0.01	(B-D)	No	significant	differences	were	found	in	the	total	distance	traveled	
(B),	 time	mobile	 (C),	 or	 in	 the	 time	 spent	 in	 the	 center	 of	 the	 open	 field	 (D).	 Data	 are	presented	as	mean	±	SEM.				 	
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